Last reviewed · How we verify

Iguratimod combined with Tofacitinib;

Nanfang Hospital, Southern Medical University · FDA-approved active Small molecule Quality 5/100

Iguratimod combined with Tofacitinib; is a Small molecule drug developed by Nanfang Hospital, Southern Medical University. It is currently FDA-approved. Also known as: Placebo of Iguratimod combined with Tofacitinib.

At a glance

Generic nameIguratimod combined with Tofacitinib;
Also known asPlacebo of Iguratimod combined with Tofacitinib
SponsorNanfang Hospital, Southern Medical University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Iguratimod combined with Tofacitinib;

What is Iguratimod combined with Tofacitinib;?

Iguratimod combined with Tofacitinib; is a Small molecule drug developed by Nanfang Hospital, Southern Medical University.

Who makes Iguratimod combined with Tofacitinib;?

Iguratimod combined with Tofacitinib; is developed and marketed by Nanfang Hospital, Southern Medical University (see full Nanfang Hospital, Southern Medical University pipeline at /company/nanfang-hospital-southern-medical-university).

Is Iguratimod combined with Tofacitinib; also known as anything else?

Iguratimod combined with Tofacitinib; is also known as Placebo of Iguratimod combined with Tofacitinib.

What development phase is Iguratimod combined with Tofacitinib; in?

Iguratimod combined with Tofacitinib; is FDA-approved (marketed).

Related